MOLLY BABL: Open Payments
NPI 1407255086 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$852 in 36 payments from 10 companies in 2025. Trend: 2023 $1,081 · 2024 $920 · 2025 $852
Food & beverage: $852
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $377 |
| AstraZeneca Pharmaceuticals LP | 6 | $168 |
| Novo Nordisk Inc | 5 | $119 |
| Otsuka America Pharmaceutical, Inc. | 4 | $88 |
| Amgen Inc. | 1 | $24 |
| E.R. Squibb & Sons, L.L.C. | 1 | $17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| GlaxoSmithKline, LLC. | 1 | $14 |
Products named: VRAYLAR, BREZTRI, REXULTI, Wegovy, QULIPTA, AIRSUPRA, UBRELVY, EVENITY.
Industry payments across NE — which companies pay providers there.
